ERBB2 and neoplasm: Data presented in this report demonstrate that splitting the total activity of the radioimmunoconjugate 227Th-trastuzumab into several injections separated in time might reduce toxicity without reducing the therapeutic efficacy in HER2-expressing tumor xenograft models in athymic nude mice.